Purpose: Romidepsin dosing recommendations for patients with malignancy and varying
degrees of hepatic dysfunction was lacking at the time of regulatory approval for T-cell …

Management of multiple myeloma (MM) has been drastically changed in the last 10 years
thanks to the introduction of novel agents, which, combined with the backbone of classical …

Background Carfilzomib is approved in the United States and Europe for treatment of
relapsed or refractory multiple myeloma (MM). This study evaluated pharmacokinetics (PK) …

The complexity of cancer chemotherapy requires pharmacists be familiar with the
complicated regimens and highly toxic agents used. This column reviews various issues …

Introduction: Multiple myeloma (MM) is the second most commonly diagnosed hematologic
malignancy and has an increasing incidence and prevalence globally, and proteasome …

Novel drugs such as immunomodulators and proteasome inhibitors have improved the
survival of patients with multiple myeloma. Like all therapeutic agents, appropriate dosing …

We propose a design for dose finding for cytotoxic agents in completely or partially ordered
groups of patients. By completely ordered groups, we mean that prior to the study, there is …

This paper proposes a trial design for locating group‐specific doses when groups are
partially or completely ordered by dose sensitivity. Previous trial designs for partially ordered …

This paper proposes a phase-I clinical trial design that uses ordinal toxicity to locate group-
specific doses when groups are partially or completely ordered prior to the start of the trial …

We propose a new design for dose finding for cytotoxic agents in two ordered groups of
patients. By ordered groups, we mean that prior to the study there is clinical information that …